| JAK2V617F negative | JAK2 V617F positive |  | ||
---|---|---|---|---|---|
 | GCC genotype | GCC genotype | Pvalue | ||
 | No ( n = 19) | Yes ( n = 23) | No ( n = 22) | Yes ( n = 35) |  |
Age, mean (SD) | 51.2 (18.3) | 57.9 (17.5) | 64.8 (14.9) | 66.1 (16.2) | 0.6466 |
Sex | Â | Â | Â | Â | Â |
   Female | 10 (52.6%) | 14 (60.9%) | 8 (36.4%) | 22 (62.9%) | 0.2965 |
   Male | 9 (47.4%) | 9 (30.1%) | 14 (64.6%) | 13 (37.1%) |  |
Splenomegaly | 11/16 (68.8%) | 4/22 (18.2%) | 5/20 (25%) | 4/33 (12.1%) | 0.0448* |
Thrombosis | 0/11 (0%) | 5/21 (23.8%) | 6/17 (35.3%) | 7/30 (23.3%) | 0.0446* |
Therapy requirement | 10/16 (90%) | 15/22 (68.2%) | 7/21 (33.3%) | 25/34 (73.5%) | 0.7408 |
Cytogenetic abnormality | 1/8(0%) | 0/16 (0%) | 2/9 (22.2%) | 4/21(19%) | 0.3618 |
MF evolution | 0/16 (0%) | 1/22 (4.5%) | 0/15 (0%) | 1/30 (3.3%) | 0.3787 |
AML evolution | 0/11 (0%) | 1/22 (4.5%) | 0/15 (0%) | 0/30 (0%) | 0.7343 |
Survival, mean (SD) | 2036 (2267) | 1883 (1643) | 1706 (1847) | 1717 (292) | 0.6528 |